Scientific background for the EDOR-Test

Similar documents
Scientific background for the EDOR-Test

Functional Assessment of Depression and Anxiety Disorders Relevant to Work Requirements

EUDOR-A multi-centre research program: A naturalistic, European Multi-centre Clinical study of EDOR Test in adult patients with primary depression

Running head: EMOTION REGULATION MODERATES PERFECTIONISM 1. Depression in College Students. Jessica Drews. Faculty Advisor: Scott Pickett

Child and Adolescent Psychiatry Trends. ADAMHS Board - 28 Oct 2014

Supplementary Methods

1. Introduction. 2. Objectives. 2.1 Primary objective

The In-betweeners: What to do with problem gamblers with mental health problems. Neil Smith National Problem Gambling Clinic CNWL NHS Trust

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

CITIES, HEALTH AND WELL-BEING NOVEMBER 2011

Beck depression inventory in general practice

Medication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015

* * * * * INTRODUCTION

ISPG Residency Education Taskforce

Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment of Depression

St George Hospital Renal Supportive Care Psychosocial Day, 10 th August Michael Noel, Supportive and Palliative Care Physician, Nepean Hospital

Adjunctive VNS in Depression...51 PSYCHIATRY. Important Reminder... Delivery of Psychiatry Alerts NOS is now 100% electronic.

Adolescent depression

Department of Psychiatry

MEDICAL POLICY EFFECTIVE DATE: 04/28/11 REVISED DATE: 04/26/12, 04/25/13, 04/24/14, 06/25/15, 06/22/16, 06/22/17

King s Research Portal

Mental health and motherhood. Why is this important? Are we doing enough? What more could we do?

Mending the Mind: treatment of the severely mentally ill

Adult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160

Depression Management

Proceedings of the International Conference on RISK MANAGEMENT, ASSESSMENT and MITIGATION

Sensitivity and specificity of depression screening tools among adults with intellectual and developmental disabilities (I/DD)

BroadcastMed Bipolar, Borderline, Both? Diagnostic/Formulation Issues in Mood and Personality Disorders

II3B GD2 Depression and Suicidality in Human Research

Classification of mood disorders

SPARRA Mental Disorder: Scottish Patients at Risk of Readmission and Admission (to psychiatric hospitals or units)

Panic disorder and anxiety symptoms are hypothesized

Referral trends in mental health services for adults with intellectual disability and autism spectrum disorders

Measurement-based Scales in Major Depressive Disorder:

Clozapine for Treating Schizophrenia: A Comparison of the States

Patients in the MIDAS Project. Exclusion Due to Bipolarity or Psychosis. Results

CIMR. What is the CIMR? May In this issue. Quarterly Newsletter. Volume 1, Issue 2

It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum

RANZCP 2010 AUCKLAND, NEW ZEALAND

What makes us ill?

DSM5: How to Understand It and How to Help

Some newer, investigational approaches to treating refractory major depression are being used.

The Neurobiology of Mood Disorders

Fabrizio Didonna, Paolo Zordan, Elena Prunetti, Denise Rigoni, Marzia Zorzi, Marco Bateni Unit for Anxiety and Mood Disorders Unit for Personality

The Benefits of Psychedelic Drug Application for Clinical Treatment of Mental Illness. Timothy Shumate. The University of Kansas School of Nursing

Clinical and public health significance of the proposed changes to the diagnosis of alcohol abuse and dependence in DSM-5

Group therapy with Pathological Gamblers: results during 6, 12, 18 months of treatment

A Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer

MENTAL HEALTH SERVICES 2010 MEDICATION

Parkinsonian Disorders with Dementia

Lecture Outline Signs and symptoms in psychiatry Adjustment Disorders Other conditions that may be a focus of clinical attention

Comorbidity of Depression and Other Diseases

Michael Berk 1,2,3, Seetal Dodd 1, Olivia M Dean 1,3, Kristy Kohlmann 1, Lesley Berk 1,4,GinSMalhi 5,6

A Manual Based Psychodynamic Therapy For Treatment Resistant Borderline Personality Disorder

Differentiating MDD vs. Bipolar Depression In Youth

Ethnicity and suicide attempt: analysis in bipolar disorder and schizophrenia

Intro to Concurrent Disorders

Defense mechanisms and symptom severity in panic disorder

Borderline Personality Disorder (BPD); then consider the costs of doing nothing, or

Study Guide Unit 3 Psych 2022, Fall 2003

THE HAMILTON Depression Rating Scale

Metacognitive therapy for generalized anxiety disorder: An open trial

Sample Report for Zero Suicide Workforce Survey

PREVALENCE OF POST TRAUMATIC STRESS DISORDER AMONG BASRAH MEDICAL STUDENTS

Supplemental data for The Prevalence of Mental Illnesses in U.S. State Prisons: A Systematic Review

In order to prove the efficacy of a drug in treating major

Depression: Assessment and Treatment For Older Adults

Eating Disorders. Anorexia Nervosa. DSM 5:Eating Disorders. DSM 5: Feeding and Eating Disorders 9/24/2015

MAPS Study MP-10 1 Study Synopsis UK April 18, 2011

A Psychiatric & Addictive Disease Healthcare System for Children and Adults

PARTIAL CARE. Partial Care (Youth/Young Adult) Service Definition

Drugs, Society and Behavior

DEPRESSION IN PRIMARY CARE

Sivik Psychosomaticism Test and Test of Operational Style - Construct Validity: Relationship with Toronto Alexithymia Scale (TAS-r)

Technical Whitepaper

Depression Disease Navigation

NQF Behavioral Health Project Phase II Submitted Measures

Application of Psychotropic Drugs in Primary Care

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

Key Messages. Around 20% of children and adolescents are estimated to have mental health disorders or problems

Setting The setting was secondary care. The economic study was carried out in the UK.

Do Violent Offenders With Schizophrenia Who Attack Family Members Differ From Those With Other Victims?

Disclosure. Overview 9/16/2016. The Collaborative Assessment and Management of Suicidality (CAMS)

European Psychiatry, 24 (5):

DEPRESSION IN CHILDHOOD AND ADOLECENCE

INTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS

S P O U S A L R ES E M B L A N C E I N PSYCHOPATHOLOGY: A C O M PA R I SO N O F PA R E N T S O F C H I LD R E N W I T H A N D WITHOUT PSYCHOPATHOLOGY

Screening for Depression and Suicide

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE

Alcoholism. Psychiatry. Alcoholism. Alcoholism. Certification. Certification

Impact of Participation in VA Evidence- Based Psychotherapy for Depression on Suicidal Ideation among Veterans

Stigma, well-being, attitudes to service use and transition to schizophrenia: Longitudinal findings among young people at risk of psychosis

Heidi Clayards Lynne Cox Marine McDonnell

Biomarkers and Mental Illness

Suicidal Ideation and Suicide Attempts in Panic Disorder and Social Phobia

Bipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN

Kim L. Gratz Department of Psychiatry and Human Behavior University of Mississippi Medical Center (UMMC)

Orientation for New Child and Adolescent Psychiatry Residents: Module Two - Assessment

Patient Manual Brainsway Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder

Overseas Corporate Scholarship Program for Clinical Leaders 2014/15

Transcription:

FROM DISCOVERY TO CLINICAL ROUTINE The Journey for EDOR started with a small, blind study in the mid-eighties and has since then gained more evidence as a method for detecting hyporeactivity as a risk factor for suicide in patients with primary depression. In this document, the most important studies connected to the EDOR-method are presented and explained. The first study 1 was made 1986 at a research ward at Karolinska Hospital in Stockholm. It was a blind study, where patients were included by the psychiatrist on duty when classified as depressed, suicidal and drug-free. Patients (n=23) were tested for 5-HIAA in liquor and electrodermal habituation, where fast habituators are hyporeactives and all others, are called reactive. Electrodermal reactivity measurements showed 15 reactive and 16 hyporeactive patients with a bimodal distribution that was statistically significant. Reactivity in patient groups Reactivity and suicides per patient group. Ref: Edman Et Al. Skin conductance habituation and cerebrospinal fluid 5-hydroxyindoleatic acid in suicidal patients. Arch Gen Psychiatry. 1986; 43:586 592. One year later, a follow-up was made showing four suicides; one with violent suicide method and three having non-violent suicide attempts, while none in patients with ideation. All suicides were hyporeactive (28.6% suicide rate), while none of the reactive patients (0%) committed suicide. Here, it was first discovered that hyporeactivity could be associated with suicide and suicide attempts, and that it was independent from 5-HIAA in liquor. In parallel to the first published paper, another study 2 was running at the psychiatric department at Linköping University. It was initiated because of the many times repeated findings of lower electrodermal activity in depressed subjects that had been seen for the first time almost a century ago. Here, patients (n=59) were almost all inpatients in a blinded study design with inclusion criteria classified as depressed according to DSM III. Electrodermal reactivity was measured according to the special habituation experiment and patients were rated clinically using two clinical scales; CPRS and GAS. The share of subjects in different groups who responded to stimuli was plotted (responsivity curve), showing a significant difference between suicide attempters and non-suicidal depressed 2

patients (see Figure). The responsivity curves also showed a great similarity in non-suicidal patients and healthy subjects. Electrodermal reactivity was not significantly related to the severity of symptoms of depression (CPRS), or the severity of general psychological disturbances (GAS). Responsivity curves Electrodermal responsivity in different groups. Ref: Thorell Et Al. Electrodermal activity in antidepressant medicated and unmedicated depressive patients and in matched healthy subjects. Acta Psychiatrica Scandinavica 1987:76:684-692. A one-year follow-up period revealed overall two suicides (3.4%), all in the group of hyporeactives (8.0%) while none in reactive (0%) subjects. This finding corroborated the results found in the previous study. Another study on electrodermal reactivity in depressed patients was running during 17 years at the depression ward in Weissenau, Germany. Over time, this led to a build-up of patient records serving as a basis for research on reactivity, depression and suicide. As a part of that study, a paper 3 was published using a sample of approximately 100 depressed inpatients with information on suicidality. The material used three matched groups, 18 subjects in each: Non-suicidal patients Suicidal ideators Suicide attempters A total of five suicides were noted; four hyporeactive and one reactive. The reactive patient was excluded from the statistical analyses because of being in a state of drug withdrawal. Analysis of reactivity between ideators, violent and non-violent attempters showed that there was a statistically significant difference across all three groups. 3

Reactivity per patient group and in suicides Electrodermal reactivity and suicides in patient groups. Ref: Keller F, et al. Suicidal behaviour and electrodermal activity in depressive inpatients. 1 Acta Psychiatr Scand 1991: 83: 324-328. The whole material in the large 17-years study was not analysed until 2011. Thorell was offered the opportunity to do that which resulted in the next paper 4. This study was partly blind since only the researchers knew the results, and only a few clinicians used it in their suicide risk assessments. Records of 783 depressed inpatients were analysed with EDR including clinical scales as Beck Depression Inventory (BDI) and STAI-Trait scale for trait anxiety. Analysis showed 250 reactive patients and 533 hyporeactive. Prevalence of hyporeactivity did not differ between age groups or gender, which agrees with results from previous research. Bipolar patients had the highest prevalence of hyporeactives, followed by unipolar patients. Prevalence of hyporeactivity in patient groups, age, gender and total. Ref: Thorell Et al. Electrodermal hyporeactivity as a trait marker for suicidal propensity in uni- and bipolar depression. J. Psychiatr. Res. 2013;47:1925 1931. 4

For clinical the scales, results confirmed a lack of correlation between ratings from clinical scales vs. the distribution of hyporeactivity. Hyporeactivity showed a very consistent share of hyporeactives across the different BDI-scores, ranging from minimal to serious classification. BDI Scores Hyporeactivity Hyporeactivity shown to be independent of total BDI-scores. Ref: Thorell Et al. Electrodermal hyporeactivity as a trait marker for suicidal propensity in uni- and bipolar depression. J. Psychiatr. Res. 2013;47:1925 1931. Due to the 17 years long duration of the study 26 patients were tested twice, with time between tests varying from 0 to 12 years. In this data, it could be shown that patients with recurrent depressions most often remain hyporeactive, and that reactive patients are prone to become hyporeactive. Out of 20 hyporeactive patients, 2 became reactive and all 6 reactive became hyporeactive, resulting in a total of 24 hyporeactives. This result, and the result from the paper by Thorell 2 indicate that hyporeactivity is a time extended condition that can last for many years. In total, 36 suicides were recorded. Overall suicide rate was 4.6%, while for hyporeactives 6.2% and reactive 2.0%. Conclusion was that hyporeactivity is a marker for suicidal propensity in uniand bipolar depression. Electrodermal reactivity after re-test of patients. Ref: Thorell Et al. Electrodermal hyporeactivity as a trait marker for suicidal propensity in uni- and bipolar depression. J.Psychiatr. Res. 2013;47:1925 1931. 5

By now, a series of studies had established a clear pattern (see graph below) on suicide rates and hyporeactivity: Suicides are overrepresented in the group of Hyporeactives, functioning as a risk marker for suicide and violent suicide attempts Hyporeactivity as a marker, is independent of gender, age and commonly used clinical scales on depressive symptoms and general psychological disturbance. Hyporeactivity varies with the share of bipolar, unipolar and other types of mood disorders. Comparisons on suicide rates Summary of suicide rates based on reactivity. However, all studies had been made either in controlled environments or at specific clinics. To study the effects of implementing the EDOR-test in clinical routine, a large, open and naturalistic multicentre study was initiated the EUDOR-A 5. This is now an ongoing project, expected to be submitted during 2018. In a continuing effort to clarify the association between hyporeactivity and suicide risk, a new study was made by Thorell and Wahlin. This study was based on an aggregation of three previously conducted blind studies showing that hyporeactivity is a strong and clear biomarker for suicide risk. 6

Odds Ratios for suicide in hyporeactives First of all, the results show that the disproportional distribution of suicides among hyporeactive patients is not a coincidence (p=0.00058). Secondly, the study shows that the suicide risk associated with hyporeactivity is 25 times higher (Odds Ratio = 25.38) compared with patients in the reactive group. These new results demonstrate that hyporeactivity is a clear and strong marker for suicide risk. Another important conclusion that can be drawn from the study results is that depressed patients whose tests show they are normally reactive belong to a group that is significantly less susceptible to suicide attempts than the average patient who seeks care for depression. REFERENCES Odds ratios for each blind study and aggregated 1, Edman G, Åsberg M, Levander S, Schalling D. Skin conductance habituation and cerebrospinal fluid 5-hydroxyindoleatic acid in suicidal patients. Arch Gen Psychiatry. 1986; 43:586 592. 2, Thorell LH, Kjellman BF, d Elia G. Electrodermal activity in antidepressant medicated and unmedicated depressive patients and in matched healthy subjects. Acta Psychiatrica Scandinavica 1987:76:684-692. 3, Keller F, et al. Suicidal behaviour and electrodermal activity in depressive inpatients. 1 Acta Psychiatr Scand 1991: 83: 324-328. 4, Thorell LH, Wolfersdorf M, Straub R, Steyer J, Hodgkinson S, Kaschka WP, et al. Electrodermal hyporeactivity as a trait marker for suicidal propensity in uni- and bipolar depression. J. Psychiatr. Res. 2013;47:1925 1931. 5, M. Sarciapone, EUDOR-A multi-centre research program: A naturalistic, European Multicentre Clinical study of EDOR Test in adult patients with primary depression BMC Psychiatry 201717:108. 6, Thorell, Wahlin, Electrodermal Hyporeactivity as a Marker for Vulnerability to Suicide in Depression, EC Psychology and Psychiatry, Volume 7 Issue 10, October 01, 2018. 7